Cantor Fitzgerald Starts Glaukos Corporation (GKOS) at Buy

Cantor Fitzgerald initiates coverage on Glaukos Corporation (NYSE: GKOS) with a Buy rating and a price target of $35.00.

Analyst Caroline Corner commented, "Glaukos is a medical device company based in Laguna Hills, CA that has a commercially available stent, the iStent, used in the treatment of glaucoma, a leading cause of blindness. The iStent received FDA premarket approval (PMA) in June 2012 and is the first and only implantable product in the new area of micro-invasive glaucoma surgery, or MIGS."

For an analyst ratings summary and ratings history on Glaukos Corporation click here. For more ratings news on Glaukos Corporation click here.

Shares of Glaukos Corporation closed at $31.95 yesterday.

You May Also Be Interested In

• TD Cowen Resumes EQT Corp. (EQT) at Hold
• RBC Capital Starts Inspire Medical Systems (INSP) at Outperform
• Loop Capital Starts DoorDash Inc. (DASH) at Buy, 'Category Killer with Stellar Execution'